Fresenius Kabi has announced the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company’s broad portfolio of injectable oncology medicines.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Fresenius Kabi developed its Fulvestrant Injection prefilled syringe to be stable at room temperature, making it the only form of Fulvestrant Injection to require no refrigeration. This can help pharmacists save on the limited refrigeration space available to them. Fresenius Kabi Fulvestrant Injection is bioequivalent to Faslodex® 1 and provides clinicians a treatment alternative.
Fresenius Kabi is a leading developer and supplier of generic injectable medicines used in the treatment of cancer, helping to make oncology therapies more affordable and accessible.
“Fresenius Kabi is pleased to continue the expansion of our oncology portfolio by offering Fulvestrant Injection,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are pleased to be the only company offering this product in a room temperature stable formulation to assist clinicians in managing their costs and workflow.”
Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy; HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine therapy or following disease progression on endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemacicilib in women with disease progression after endocrine therapy.